Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Income from Continuing Operations (2021 - 2025)

SAB Biotherapeutics' Income from Continuing Operations history spans 5 years, with the latest figure at 15132954.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 52.19% year-over-year to 15132954.0; the TTM value through Dec 2025 reached 47761995.0, down 46.27%, while the annual FY2025 figure was 47761995.0, 13.87% down from the prior year.
  • Income from Continuing Operations reached 15132954.0 in Q4 2025 per SABSW's latest filing, down from 12067028.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1409834.0 in Q1 2021 to a low of 22856763.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 7923471.55, with a median of 7344637.5 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: crashed 845.93% in 2023, then surged 56.5% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 11551496.0 in 2021, then soared by 32.05% to 7848966.0 in 2022, then crashed by 191.21% to 22856763.0 in 2023, then skyrocketed by 56.5% to 9943342.0 in 2024, then crashed by 52.19% to 15132954.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Income from Continuing Operations are 15132954.0 (Q4 2025), 12067028.0 (Q3 2025), and 9782844.0 (Q2 2025).